welcomed its first tenant – GlycoSeLect UK – into its new home at the Institute for Learning, Research and Innovation at The James Cook University Hospital. GlycoSeLect (UK) Ltd, specialists in the development of glycoprotein separation technology for analysis and manufacturing uses in pharmaceutical companies, announces the establishment of a new laboratory facility in South Tees Bio-incubator.
GlycoSeLect’s vision is to be the leading company in the development and manufacture of glycoprotein analytical and manufacturing products for the life science industries. The UK has a world renowned network of pharmaceutical companies making it an excellent environment in which to further develop and commercialise GlycoSeLect’s innovative RPL technology for glycoprotein separation. The South Tees Bio-Incubator laboratory provides the infrastructure and a contact hub to facilitate product and business development with GlycoSeLect’s UK customers.
The Trust’s Director of Innovation and Consultant Cardiac Surgeon Professor Andrew Owens said:
“It’s now widely acknowledged that research, innovation and entrepreneurship are crucial driving factors for the North East’s long-term efficiency, competitiveness and economic growth and initiatives such as this mean the Trust can develop deep and high value partnerships.”
Dr Hakim Yadi, CEO of the Northern Health Science Alliance, explained:
“The North’s life sciences economy is recognised internationally and already contributes £10.8bn to the UK economy. Projects such as The South Tees bio-incubator build on that recognition helping to drive further jobs, investment and innovations into the North. I am looking forward to working with the South Tees incubator and the CPI on a new model of innovation between our respective organisations.”
Dr Chris Dowle, Director of Future Business in Healthcare at CPI added:
“We are delighted to work with the team at South Tees developing this and a series of other exciting healthcare projects where we can focus our technologists and business experts to help to deliver solutions at the front-line. Because of market demand we have plans to extend bio-incubation facilities here in the Tees Valley to join with other supply chain expertise in projects such as the biotherapeutic factories of the future/new healthcare solutions centre planned for 2018.”
Robert Dunne, CEO of GlycoSeLect, said:
“GlycoSeLect is pleased to establish an analytical applications research laboratory which will enhance interactions with biopharmaceutical and other life science industry companies in the UK. The North East of England has a tremendous reputation for welcoming companies from around the world and nurturing their growth and success which we will leverage. Our team are delighted to continue their connections with the Biologics Unit of CPI following our successful Early Stage Feasibility project supported by an award from InnovateUK. The South Tees Bio-Incubator provides our team with an excellent working environment and facilities needed to grow our business in a renowned medical research campus. ”
The South Tees Bio-incubator has been set up to allow early-stage biotechnology and life sciences companies become established and realise potential commercial success, by providing access to specialist facilities, expert advice and shared laboratory space.
A strategic partnership between the South Tees Hospitals NHS Foundation Trust, NHSA (Northern Health Science Alliance) and the CPI (Centre for Process Innovation), it has already
GlycoSeLect UK Announces the Establishment of a New Research Laboratory in South Tees Bio-Incubator
Published August 10th 2016
Notes to Editors
About GlycoSeLect Ltd
GlycoSeLect Ltd is an early-stage BioTechnology company developing proprietary next-generation, highly specific and cost-efficient tools for the analysis, characterisation and purification of biotherapeutics. Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of Recombinant Prokaryotic Lectisn (RPLs); enhanced glycoselective bioaffinity proteins that enable efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect’s current family of RPLs target a range of galactose, mannose and sialic acid glycoprofiles and are associated with market leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness.
GlycoSeLect UK Ltd was established in 2015 to support further development, provide wider geographic reach and drive commercialisation
About South Tees Hospitals NHS Foundation Trust – Institute of Learning, Research and Innovation
South Tees Institute of Learning, Research and Innovation brings together all of the Trust’s learning, research, training development functions into one and has developed strengths and partnerships with cutting edge organisations and stakeholders across the NHS, education and clinical industry landscapes.
The Institute is recognised by ethical and professional bodies with the ability to lobby in support of the workforce, patients, carers and associated organisations and bodies who strive to continuously deliver above excellence services to patients, either in day to day care, in advancing the NHS landscape and/or through research to make clinical treatment based advances.
Its ethos is collaboration with established partnerships with a wide range of local, regional, national and international organisations including primary and secondary care strategic partners, universities and other academic partners, pharmaceutical companies, private industry, voluntary sector, charitable sector and awarding bodies.
For further information about the Bio-incubator, contact Andrew Owens on 01642 854728.
About The Northern Health Science Alliance
The Northern Health Science Alliance Ltd (NHSA) is a partnership established by the leading Universities and NHS Hospital Trusts in the North of England to improve the health and wealth of the region by creating an internationally recognised life science and healthcare system.
The NHSA links eight universities, eight NHS Teaching Trusts and four Academic Health Science Networks (AHSNs). Together the Alliance and the four Northern AHSNs cover a patient population of over 15 million people.
The NHSA acts as a single portal bringing together research, health science innovation and commercialisation to provide benefits for researchers, universities and patients. Visit www.thenhsa.co.uk
About Centre for Process Innovation
The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult. We use applied knowledge in science and engineering combined with state of the art development facilities to enable our clients to develop, prove, prototype and scale up the next generation of products and processes.
Our open innovation model enables clients to develop products and prove processes with minimal risk. We provide assets and expertise so our customers can demonstrate the process before investing substantial amounts of money in capital equipment and training. New products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale.
By utilising our proven assets and expertise companies can take their products and processes to market faster. There is no down time in production as all of the process development is completed offsite and our technology transfer and engineering teams can help companies to transfer the product or process into full scale production at speed.